Information Technology Award Announced for Pharmacy in 2009

First DataBank Europe (FDBE) in association with The Guild of Healthcare Pharmacists (GHP) and the UK Clinical Pharmacy Association (UKCPA) announced the 2009 FDBE/GHP/UKCPA Information Technology Award. The aim of the annual award, which is in its seventh year, is to encourage, support and promote information technology initiatives and best practice in the use of IT in hospital pharmacy. In particular, initiatives are sought where IT has made a positive difference to the provision of pharmaceutical services or resulted in direct benefit to the patients or staff. The award, sponsored by FDBE and aimed at pharmacy departments and individuals, is for the sum of two thousand five hundred pounds.

Projects may be related to patient care, clinical services, medicines management, decision support, electronic prescribing, or any other IT application that improves pharmaceutical services. This year's award has been won by the Pharmacy Department at the Northumbria Healthcare NHS Trust. The project team was commended for successfully developing a Medicines Management e learning package, accessible and relevant to all staff involved in the medicines management process across all knowledge levels and staff groups.

Last year's winner was the University College London Hospitals NHS Trust which created a solution which used IT to manage and electronically store information about clinical trials taking place within the trust. In 2006 the Queen’s Medical Centre Pharmacy Department who won the award for its development of a networked IT system to improve the on-call pharmacy service.

Neil Kirby, Member of the IT Interest Group enthused said, "We are delighted that FDBE has chosen to continue to support this award. The entries we have received over the last six years have been of a very high standard and have demonstrated the positive impact that IT can have upon the way pharmacists work and the way in which services are delivered. We hope that this award will continue to highlight some of the most successful projects and inspire others in the use of information technology."

The deadline for entries is Wednesday 31 December 2008 and the award will be presented in the spring of 2009. To apply please see the 2009 award leaflet available soon via the awards pages at www.ukcpa.org or www.ghp.org.uk.

About First DataBank Europe
First DataBank Europe (FDBE) is the UK's leading provider of drug knowledge bases and active clinical decision support software. Through the effective implementation of our products, we enable safer prescribing and dispensing at the point of care. NHS Connecting for Health has chosen FDBE to provide drug-related clinical decision support.

Patient safety is the driving force behind our business. With over 25 years' experience of maintaining, developing and implementing drug knowledge bases across the entire healthcare spectrum, FDBE has unrivalled expertise and knowledge in the field of clinical decision support. Our Multilex Drug Data File - the UK's most comprehensive and widely used drug knowledge base – is in daily use by thousands of healthcare professionals in the UK.

Working closely with a wide range of leading system suppliers to integrate our products into clinical systems across primary care, secondary care, community pharmacy and other healthcare environments, FDBE delivers real patient safety benefits.

For further information visit www.firstdatabank.co.uk.

Most Popular Now

BioNTech's statement on patent infringement lawsui…

BioNTech SE (Nasdaq: BNTX, "BioNTech") published an official statment: "BioNTech is aware of reports that Moderna has sued Pfizer and BioNTech, alleging that COMIRNATY® i...

Xenpozyme™ (olipudase alfa-rpcp) approved by FDA a…

The U.S. Food and Drug Administration (FDA) has approved Xenpozyme™ (olipudase alfa-rpcp) for the treatment of non-central nervous system (non-CNS) manifestations of acid...

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Research reveals widespread use of ineffective COV…

Monoclonal antibodies are laboratory-designed treatments tailor-made to fight specific infections. In early 2021, the U.S. Food & Drug Administration issued emergency use...

Efficacy, cash and more will increase booster shot…

The more effective the COVID-19 booster, the more likely people are to get it, according to new Cornell research. And they are more likely to accept the booster shot with...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...